Multidisciplinary treatment with immune checkpoint inhibitors for advanced stage hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is a cytotoxic chemotherapy-resistant tumor and most HCCs arise in a background of liver cirrhosis of various causes. Although the IMBrave150 trial showed remarkable advancements in the treatment of unresectable HCC with atezolizumab plus bevacizumab (AteBeva), therape...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Ahlim, Lee, Jaejun, Yang, Hyun, Sung, Soo-Yoon, Jeon, Chang Ho, Kim, Su Ho, Choi, Moon Hyung, Lee, Young Joon, Chun, Ho Jong, Bae, Si Hyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Liver Cancer Association 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035713/
https://www.ncbi.nlm.nih.gov/pubmed/37383536
http://dx.doi.org/10.17998/jlc.2022.03.04

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035713/
https://www.ncbi.nlm.nih.gov/pubmed/37383536
http://dx.doi.org/10.17998/jlc.2022.03.04

Ejemplares similares